Service Codes
BI = Biostatistics
CL = Clinical
DM = Data Management
FS = Full Service
MS = Medical Safety
MW = Medical Writing
RA = Regulatory Affairs
Phase | Indication | Therapeutic Area | Services | Number of Sites | Number of patients |
---|---|---|---|---|---|
1 | Metastatic Cancer | Oncology | FS | 1 | 21 |
1 | KRAS Mutant Metastatic Colorectal Cancer | Oncology | BI, DM | 3 | 25 |
1 | KRAS Mutant Metastatic Colorectal Cancer | Oncology | BI, DM | 3 | 36 |
1 | Autoimmune | Endocrinology | BI, DM | 1 | 46 |
1 | Advanced Solid Tumors | Oncology | DM | 3 | 27 |
1 | Chronic Lymphocytic Leukemia | Oncology | BI, DM | 5 | 10 |
1 | Herpes Zoster | Infectious Diseases | DM | 5 | 700 |
1 | Extensive, recurrent or metastatic sarcoma, melanoma, or carcinoma | Oncology | CL, RA | 20 | 96 |
1 | Prevention of MI and Stroke | Cardiovascular | FS | 1 | 18 |
1 | Infectious Disease | Infectious Disease | FS | 1 | 8 |
1 | Depression | CNS | CL | 1 | 160 |
1 | Motion Sickness | CNS | CL | 1 | 150 |
1 | Severe Combined Immunodeficiency | Rare Diseases | MS | 1 | 42 |
2 | Plaque Psoriasis | Dermatology | BI, DM, MS, MW | 5 | 60 |
2 | Diabetic Macular Edema | Ophthalmology | BI, CL, DM, MW | 8 | 40 |
2 | Glioblastoma and Gliosarcoma | Oncology | DM, CL | 1 | 25 |
2 | HIV Cardiovascular Risk Resuction | Cardiovascular | CL, DM, MW | 1 | 64 |
2 | Meibomian Gland Dysfunction Associated Dry Eye Disease | Ophthalmology | BI, CL, DM, MW | 5 | 90 |
2 | Advanced Pancreatic Adenocarcinoma | Oncology | DM | 2 | 34 |
2 | Metastatic Melanoma | Oncology | DM | 1 | 14 |
2 | Squamous Cell Cacinoma of the Lung | Oncology | DM | 12 | 32 |
2 | Dry Eye | Ophthalmology | BI, DM | 2 | 62 |
2 | Hereditary Angioedema | Endocrinology | CL | 15 | 30 |
2 | PET Study | CNS | FS | 1 | 20 |
2 | Bipolar Depression | CNS | FS | 1 | 108 |
2 | Motion Sickness in Hepatically Impaired Patients | CNS | CL | 1 | 24 |
2 | Motion Sickness in Renally Impaired Patients | CNS | FS | 1 | 8 |
2 | Motion Sickness on Commercial Boat | CNS | FS | 1 | 300 |
2 | Plaque Psoriasis | Dermatology | BI, DM, MS, MW | 4 | 69 |
2 | Atopic Dermatitis | Dermatology | BI, CL, DM, MW | 1 | 72 |
3 | Squamous Cell Carcinoma of the Head and Neck | Oncology | BI, CL, DM | 58 | 184 |
3 | Squamous Cell Carcinoma of the Head and Neck | Oncology | BI, MW | 58 | 184 |
3 | Motion Sickness | CNS | FS | 1 | 60 |
3 | Motion Sickness on Commercial Boat and at 3 CNS Sites | CNS | FS | 1 | 102 |
3 | Motion Sickness on Commercial Boat and at 3 CNS Sites (Elderly Population) | CNS | FS | 1 | 100 |
1/2 | Open-angle Glaucoma or Ocular Hypertension | Ophthalmology | BI, CL, DM, MS, MW | 1 | 50 (18) |
1/2A | Recurrent Grade IV Glioma | Oncology | FS | 9 | 49 |
1B | Malignant Pleural Mesothelioma | Oncology | BI, CL, DM | 5 | 60 |
2A | Molluscum Contagiosum in Pediatric Subjects | Dermatology | BI, DM, MS | 1 | 60 |
Device | Knee Replacement | Musculoskeletal | CL | 6 | 260 |
Device Ceasibility Study | Vision Improvement | Ophthalmology | FS | 22 | 396 |
Device Crossover Study | Vision Improvement | Ophthalmology | FS | 11 | 198 |
For Approval | Astigmatism Soft Contact Lenses when worn on a daily basis | Ophthalmology | FS | 2 | 120 |
1 | Diabetes | Endocrinology | BI, DM | 1 | 22 |
1 | Healthy Volunteers | Endocrinology | BI, DM | 1 | 14 |
1 | Solid Tumors | Oncology | BI, DM | 5 | 27 |
1 | Advanced Solid Tumors or Lymphoma | Oncology | BI, DM | 3 | 107 |
1 | Lymphocytic Leukemia | Oncology | BI, DM | 1 | 8 |
1 | Lymphocytic Leukemia | Oncology | BI, DM | 1 | 12 |
1 | Lymphocytic Leukemia | Oncology | BI, DM | 1 | 2 |
1 | Metastatic Solid Tumors | Oncology | BI, DM | 1 | 18 |
1 | Advanced Malignancies | Oncology | BI, DM | 2 | 17 |
1 | Advanced Malignancies | Oncology | BI, DM | 3 | 25 |
1 | Advanced Malignancies | Oncology | BI, DM | 3 | 38 |
1 | Oncology | Oncology | BI, CL, DM | 1 | 5 |
1 | Chronic Lymphocytic Leukemia | Oncology | BI, DM | 3 | 15 |
1 | Diabetic Macular Edema | Ophthalmology | BI, CL, DM | 6 | 22 |
1 | Age-Related Macular Degeneration | Ophthalmology | DM | 8 | 56 |
1/2 | Malignant Gliomas | Oncology | BI, DM | 3 | 18 |
1/2 | Advanced Malignancies | Oncology | BI, DM | 2 | 34 |
1/2 | Oncology | Oncology | BI | 4 | 20 |
1/2A | Basal Cell Carcinoma | Oncology | FS | 3 | 27 |
1/2A | Scar Formation and Keloid Recurrence Following Surgical Keloidectomy | Dermatology | FS | 5 | 30 |
1A/1B | Advanced Metastatic Solid Tumors and NSCLC | Oncology | BI, DM, MS, MW | 7 | 84 |
1A/1B | Recurrent Head and Neck Cancer | Oncology | BI, CL, DM, MS, MW | 7 | 40 |
IDE | Bifurcated Stent Graft Study with a 5-Year Follow-up | Cardiovascular | BI, DM | 15 | 64 |
IDE | Endovascular Aneurysms | Cardiovascular | BI, DM | 2 | 15 |
IDE | Endovascular Aneurysms | Cardiovascular | BI, DM | 8 | 34 |
IDE | Endovascular Aneurysms | Cardiovascular | BI, DM | 20 | 96 |
IDE | Abdominal Aortic Aneurysms | Cardiovascular | DM | 3 | 15 |
IDE | Endovascular Aneurysms | Cardiovascular | DM | 20 | 192 |
2 | Atopic Dermatitis | Dermatology | BI, DM, MS, MW | 5 | 71 |
2 | Sickle-Cell Anemia, Sickle Beta-Thalassemia | Hematology | BI, CL, DM | 5 | 80 |
2 | Sickle-Cell Anemia – Exercise Study | Hematology | BI, CL, DM | 1 | 15 |
2 | Advanced Cancers including Head, Neck, and Esophageal Cancers | Oncology | BI, DM | 3 | 16 |
2 | Bone and Soft Tissue Sarcomas Metastatic to the Lung | Oncology | BI, DM | 4 | 53 |
2 | Squamous Cell Carcinoma of the Head and Neck | Oncology | BI, DM | 2 | 14 |
2 | Non-Small Cell Lung Cancer accompanied by KRAS or EGFR Activated Tumors | Oncology | BI, DM | 2 | 37 |
2 | Coronary Artery Disease | Cardiovascular | DM | 15 | 200 |
2 | Plaque Psoriasis | Dermatology | DM | 12 | 260 |
2 | Atopic Dermatitis | Dermatology | BI, DM, MS, MW | 5 | 72 |
2 | Diabetic Gastroparesis | Endocrinology | DM | 6 | 89 |
3 | Sickle-Cell Anemia, Sickle Beta-Thalassemia | Hematology | FS | 31 | 230 |
3 | Motion Sickness | CNS | BI, CL, DM, MW | 1 | 360 |
3 | Motion Sickness | CNS | BI, CL, DM, MW | 1 | 30 |
3 | Motion Sickness | CNS | FS | 1 | 54 |
IND | Treatment-Resistant Major Depressive Disorder | CNS | RA | 1 | 72 |
4 | Vitreomacular Adhesion | Ophthalmology | BI, CL, DM | 22 | 134 |
N/A | Dry AMD | Ophthalmology | DM, MS | 2 | 15 |
N/A | Oncology | Oncology | BI, DM | 1 | 19 |
N/A | Oncology | Oncology | BI, DM | 1 | 19 |
N/A | Oncology | Oncology | BI, DM | 2 | 33 |
N/A | Oncology | Oncology | BI, DM | 2 | 25 |
N/A | Oncology | Oncology | BI, DM | 1 | 6 |
N/A | Oncology | Oncology | BI, DM | 1 | 12 |
N/A | Transmyocardial Revascularization | Cardiovascular | BI, DM | 6 | 81 |
N/A | Facial Acne Vulgaris | Dermatology | DM | 1 | 266 |
N/A | Hematologic Malignancies | Hematology | DM | 4 | 90 |
Pilot Study | Autism | CNS | CL | 1 | 20 |
PMA | Soft Contact Lenses worn on a 7-Day Extended Wear | Ophthalmology | FS | 34 | 818 |
Proof of Concept | Blood Loss Monitoring | Cardiovascular | CL, MS, RA | 1 | 20 |
Proof of Concept | Blood Loss Monitoring | Cardiovascular | CL, MS, RA | 1 | 20 |
TBD | Prostate Cancer | Oncology | CL | 1 | 167 |
TBD | Renal Transplant Recipients | Urology | CL | 6 | 200 |